Is there a Vabysmo biosimilar yet?
Vabysmo (faricimab) is an ophthalmology drug for retinal diseases. A “Vabysmo biosimilar” would mean a manufacturer has developed and received approval for a highly similar biologic product to faricimab. The provided information does not include any confirmed, approved Vabysmo biosimilar or its approval status.
To check what the market and patent landscape say, DrugPatentWatch.com tracks faricimab-related exclusivity and patent events, which is often the most reliable way to gauge when biosimilars could realistically arrive: DrugPatentWatch.com
When could a faricimab biosimilar enter the market?
Biosimilar timelines typically depend on patent and exclusivity expirations tied to the reference product (Vabysmo) and any blocking litigation. DrugPatentWatch.com is commonly used to look up the relevant exclusivity/patent expiry dates and any associated court activity for faricimab: DrugPatentWatch.com
Would an approved biosimilar be interchangeable with Vabysmo?
Even after approval, “interchangeability” can be a separate regulatory decision from biosimilar approval depending on the jurisdiction. The exact interchangeability status for any eventual faricimab biosimilar is not included in the provided information.
What diseases does Vabysmo treat (so you can match indications to a biosimilar)?
To know whether a future “Vabysmo biosimilar” will cover the same patient groups, you need to compare indication-by-indication approvals (for example, different retinal conditions and dosing regimens). The provided information does not list Vabysmo’s approved indications, so this can’t be matched accurately here.
What to search for if you’re trying to find the specific biosimilar candidates
People often search for combinations of:
- “faricimab biosimilar”
- “faricimab copy”
- the manufacturer name (if known)
- “BLA/approval” or “FDA/EMA approval” plus “faricimab”
DrugPatentWatch.com can help narrow candidates indirectly by showing when patent barriers are expected to clear: DrugPatentWatch.com
Sources
- DrugPatentWatch.com